Watson C
Amgen Inc., Thousand Oaks, CA, USA.
ANNA J. 1999 Dec;26(6):629-32.
Hyporesponse to Epoetin alfa therapy can be minimized by categorizing patients on the basis of trends in hemoglobin/hematocrit levels and initiating a continuous quality improvement effort that focuses on subnormal outcomes. An algorithm is provided that clinicians can use to proactively assess common causes that contribute to hyporesponse and limit the effect on patient outcomes.
通过根据血红蛋白/血细胞比容水平的趋势对患者进行分类，并启动一项关注低于正常水平结果的持续质量改进措施，可以将对促红细胞生成素α治疗的低反应降至最低。本文提供了一种算法，临床医生可用于主动评估导致低反应的常见原因，并限制其对患者治疗结果的影响。
